INIS Narrows Losses Amid Revenue Growth, Strategic Shifts

TL;DR

**INIS is slowly turning the corner with better sales and smaller losses, but that big asset sale is a ticking time bomb that could make or break them.**

AI Summary

INTERNATIONAL ISOTOPES INC (INIS) reported a net loss of $273,479 for the six months ended June 30, 2025, an improvement from a net loss of $387,496 in the same period of 2024. Revenue from product sales increased to $6,894,220 for the six months ended June 30, 2025, up from $6,073,691 in 2024, representing a 13.5% increase. Gross profit also rose to $4,173,596 from $3,883,622 year-over-year. Operating expenses increased slightly to $4,373,453 from $4,329,942. The company generated $310,446 in net cash from operating activities for the first half of 2025, compared to $288,597 in 2024. Strategic initiatives include focusing on Theranostics Products, Cobalt Products, and Nuclear Medicine Standards, and developing its Medical Device segment with assets from AMICI, Inc. A significant risk is the potential sale of the Fluorine Products segment and Planned Uranium De-Conversion Facility for $12.5 million, which faces a March 31, 2026, closing deadline and buyer-requested extensions. The company expects current cash, operations, and potential financing to fund operations for the next twelve months.

Why It Matters

For investors, INIS's reduced net loss and increased revenue signal a potential turnaround, but the reliance on the uncertain $12.5 million sale of the Fluorine Products segment introduces significant risk. Employees in the core Theranostics, Cobalt, and Nuclear Medicine Standards segments may see increased stability, while those tied to the Fluorine Products segment face uncertainty. Customers could benefit from the company's focus on core product lines and new medical device offerings. The broader market for nuclear medicine and isotopes could see increased competition and innovation from INIS's strategic alliances, such as the joint venture with Alpha Nuclide Inc. for the China market.

Risk Assessment

Risk Level: medium — The company has incurred substantial losses since inception, with an accumulated deficit of $127,594,764 as of June 30, 2025. While net loss improved to $273,479 for the six months ended June 30, 2025, the company's future liquidity is heavily tied to the contingent sale of its Fluorine Products segment and De-Conversion Facility for $12.5 million, which has an 'Outside Date' of March 31, 2026, and a buyer-requested extension that was denied, indicating potential deal fragility.

Analyst Insight

Investors should monitor the progress of the Fluorine Products segment sale closely, as its successful completion is crucial for INIS's long-term liquidity and capital funding. Evaluate the company's ability to sustain revenue growth in its core segments and the impact of new strategic alliances, such as the Alpha Nuclide Inc. joint venture, on future profitability before making any investment decisions.

Financial Highlights

debt To Equity

3.09

revenue

$6,894,220

operating Margin

-2.90%

total Assets

$17,510,099

total Debt

$10,135,960

net Income

-$273,479

eps

-$0.0005

gross Margin

60.54%

cash Position

$1,859,424

revenue Growth

+13.5%

Revenue Breakdown

Key Numbers

• $6.89M — Product Sales (Increased from $6.07M in 2024 for the six months ended June 30, 2025, showing a 13.5% growth.)
• $273K — Net Loss (Reduced from $387K in 2024 for the six months ended June 30, 2025, indicating improved financial performance.)
• $310K — Net Cash from Operating Activities (Increased from $288K in 2024 for the six months ended June 30, 2025, demonstrating stronger operational cash generation.)
• $12.5M — Potential Sale Proceeds (Expected from the sale of the Fluorine Products segment, critical for future liquidity.)
• 528,010,308 — Common Shares Outstanding (As of June 30, 2025, reflecting share dilution from various issuances.)
• $127.59M — Accumulated Deficit (As of June 30, 2025, highlighting historical losses.)

Key Players & Entities

• INTERNATIONAL ISOTOPES INC. (company) — registrant
• AMICI, Inc. (company) — seller of medical device assets
• Alpha Nuclide Inc (company) — joint venture partner for China market
• Phantech LLC (company) — joint venture partner for PhanQual
• Nuclear Regulatory Commission (regulator) — issued construction and operating license
• $273,479 (dollar_amount) — net loss for six months ended June 30, 2025
• $6,894,220 (dollar_amount) — sale of product for six months ended June 30, 2025
• $12.5 million (dollar_amount) — proceeds from potential sale of Fluorine Products segment
• March 31, 2026 (date) — maximum closing date for Fluorine Products segment sale
• Idaho Falls, Idaho (location) — headquarters and primary operations

FAQ

Risk Factors

• Potential Sale of Fluorine Products Segment [high — financial]: The company faces a March 31, 2026, deadline for the $12.5 million sale of its Fluorine Products segment and Planned Uranium De-Conversion Facility. Buyer-requested extensions introduce uncertainty regarding the timing and completion of this significant transaction, which is crucial for future liquidity.
• Dependence on Key Product Segments [medium — operational]: The company's strategic focus on Theranostics Products, Cobalt Products, and Nuclear Medicine Standards, along with the development of its Medical Device segment, indicates a concentration of future growth expectations in these areas. Any disruption or underperformance in these specific segments could materially impact financial results.
• Sustained Accumulated Deficit [medium — financial]: As of June 30, 2025, the company has an accumulated deficit of $127.59 million. While the net loss has narrowed, the significant historical losses highlight the ongoing challenge of achieving sustained profitability.
• Reliance on Current Cash and Financing [high — financial]: The company expects its current cash, operations, and potential financing to fund operations for the next twelve months. Any inability to secure necessary financing or unexpected cash outflows could jeopardize its ability to continue as a going concern.

Industry Context

The nuclear medicine and isotopes industry is characterized by high regulatory barriers, specialized manufacturing processes, and a growing demand for diagnostic and therapeutic agents. Key trends include the development of novel radiopharmaceuticals for cancer treatment (Theranostics) and advancements in medical imaging technologies. Competition often comes from established players with significant R&D capabilities and market access.

Regulatory Implications

The company operates in a highly regulated sector, requiring strict adherence to FDA and other international health and safety regulations for its products. Changes in regulatory requirements or delays in approvals for new products or manufacturing processes can significantly impact operations and market access.

What Investors Should Do

1. Monitor the progress and potential closing of the Fluorine Products segment sale, as this is critical for future liquidity and strategic direction.
2. Analyze the performance of the Theranostics Products, Cobalt Products, and Nuclear Medicine Standards segments to assess the company's ability to drive future growth.
3. Evaluate the company's ability to secure additional financing, given the reliance on current cash and potential funding for the next twelve months.
4. Assess the impact of the accumulated deficit and the path towards sustained profitability.

Key Dates

• 2025-06-30: Six Months Ended — Reporting period showing revenue growth and reduced net loss compared to the prior year.
• 2026-03-31: Fluorine Products Segment Sale Deadline — Critical deadline for the potential $12.5 million sale, impacting future liquidity.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative balance in retained earnings. (Indicates the company's history of losses, standing at $127.59 million as of June 30, 2025.)

Mandatorily Redeemable Convertible Preferred Stock

A class of preferred stock that has a contractual obligation for the issuer to redeem it at a specified future date or upon the occurrence of a specific event, and it can be converted into common stock. (Represents a significant liability of $4,063,000, impacting the company's capital structure and potential future cash outflows.)

Right-of-use asset

An asset representing a lessee's right to use an underlying asset for the lease term, recognized under ASC 842 lease accounting standards. (The company has significant operating lease right-of-use assets totaling $2,785,839 in current and $2,637,598 in long-term portions as of June 30, 2025.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, INTERNATIONAL ISOTOPES INC. reported a 13.5% increase in product sales to $6.89 million, alongside a reduction in net loss to $273,479 from $387,496 in the prior year. Gross profit improved, and net cash from operations increased. However, operating expenses saw a slight rise, and the company continues to carry a substantial accumulated deficit. A new significant risk factor involves the potential sale of the Fluorine Products segment with a looming deadline.

Key Financial Figures

• $0.01 — , the number of shares of common stock, $0.01 par value, outstanding was 528,104,105

Filing Documents

• inis20250630_10q.htm (10-Q) — 1032KB
• ex_825316.htm (EX-31.1) — 9KB
• ex_825317.htm (EX-31.2) — 8KB
• ex_825318.htm (EX-32.1) — 5KB
• ex_825319.htm (EX-32.2) — 5KB
• 0001437749-25-026370.txt ( ) — 5133KB
• inis-20250630.xsd (EX-101.SCH) — 37KB
• inis-20250630_cal.xml (EX-101.CAL) — 43KB
• inis-20250630_def.xml (EX-101.DEF) — 316KB
• inis-20250630_lab.xml (EX-101.LAB) — 291KB
• inis-20250630_pre.xml (EX-101.PRE) — 338KB
• inis20250630_10q_htm.xml (XML) — 756KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statement of Stockholder ' s (Deficit) Equity for the Three and Six Months Ended June 30, 2025 and 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 8 Item 4.

Controls and Procedures

Controls and Procedures 28

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 5. Other Information 28 Item 6. Exhibits 29

Signatures

Signatures 30 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) June 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 1,859,424 $ 1,945,523 Accounts receivable 1,732,939 1,521,380 Inventories 670,542 820,893 Prepaids and other current assets 311,984 698,030 Total current assets 4,574,889 4,985,826 Long-term assets Restricted cash 1,462,280 1,431,710 Property, plant and equipment, net 3,397,022 3,297,769 Capitalized lease disposal costs, net 614,698 639,286 Financing lease right-of-use asset — 826 Operating lease right-of-use asset 2,785,839 2,047,733 Goodwill 1,384,255 1,384,255 Patents and other intangibles, net 3,291,116 3,373,563 Total long-term assets 12,935,210 12,175,142 Total assets $ 17,510,099 $ 17,160,968 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 935,026 $ 861,883 Accrued liabilities 1,254,250 1,494,665 Unearned revenue 568,816 513,317 Current portion of operating lease right-of-use liability 189,780 150,532 Current installments of notes payable 160,385 308,399 Total current liabilities 3,108,257 3,328,796 Long-term liabilities Accrued long-term liabilities 18,750 37,500 Related party notes payable, net of current portion 1,620,000 1,620,000 Notes payable, net of current portion 215,414 278,897 Asset retirement obligation 1,581,198 1,544,788 Operating lease right-of-use liability, net of current portion 2,637,598 1,940,979 Mandatorily redeemable convertible preferred stock 4,063,000 4,063,000 Total long-term liabilities 10,135,960 9,485,164 Total liabilities 13,244,217 12,813,960 Stockholders' equity Common stock, $ 0.01 par value; 750,000,000 shares authorized; 528,010,308 and 523,553,435 shares issued and outstanding, respectively 5,280,103 5,235,534 Additional paid in capital 126,580,543 126,432,759 Accumulated deficit (

View Full Filing

View this 10-Q filing on SEC EDGAR